- Kolosis bone grafts continue to gain widespread adoption, now available in over 370 hospitals and surgical facilities across 46 states
- The company’s grafts were utilized in over 12,000 fusion procedures in 2022, doubling the number from the previous year
- Kolosis BIO also expanded its national footprint, now leveraging more than 150 independent distributors in the orthopedic space
- Kore Fiber, the company’s flagship product, saw continued market success and positive clinical performance, now available on over 60 health systems and GPO contracts
SALT LAKE CITY, Utah–(OrthoSpineNews)– Kolosis BIO, LLC (Kolosis), a pure-play biologics company and an exclusive bone graft partner to MTF Biologics, announced today its 2022 results and 2023 expectations. The company nearly doubled its revenue in 2022, driven by the continued success of its flagship product, Kore Fiber, and its pre-hydrated DBM tissue-form, Prime HD.
“We are thrilled with the success we achieved in 2022,” said Collin Begley, CEO of Kolosis. “The expanded market adoption of Kore Fiber and the continued strong performance of Prime HD have been major drivers of our success. We are committed to continuing our focus on innovation and developing game-changing, disruptive technologies in 2023.”
Kolosis President, Keegan Begley, added, “Our value proposition in the market as a pure-play biologics company is extremely compelling with our best-in-class aseptically processed technologies from MTF and rapidly expanding contract access for our bone graft portfolio. We have made considerable advancements in the area of research and providing clinical evidence for our existing products, and we expect to see significant publications and developments in the coming year.”
Kolosis anticipates strong revenue growth in 2023 as it continues to expand its sales force, novel product offering, and scientific evidence for its technologies.
